Pharmaceutical

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Small-Cell Lung Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Small-Cell Lung Cancer.

Apr 19, 2024 - 00:00
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Small-Cell Lung Cancer.
Read the original article

Tags:

Previous Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hepatocellular Carcinoma...

Next Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Hodgkin Lymphoma: Li...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How a six-in-one vaccine could soon help the world get rid of polio for good

How a six-in-one vaccine could soon help the world get ...

Jun 24, 2023

Opinion: The best way for the NIH to reduce drug prices is to address drug spending

Opinion: The best way for the NIH to reduce drug prices...

Aug 15, 2023

Lilly’s EBGLYSS gains FDA approval for patients aged 12 and older

Lilly’s EBGLYSS gains FDA approval for patients aged 12...

Sep 16, 2024